Advanced Medical Device Show 2027 Conference
THE DEVICE ECONOMY 2030
Who Wins the Next Generation of MedTech — and What Will It Take to Get There?
Two commercially focused days following the route from product and evidence through buyer adoption, procurement, reimbursement, distribution, partnerships, manufacturing and scale.
INVITED SPEAKERS
Tim Schmid
Executive Vice President, Worldwide Chairman, MedTech
Johnson & Johnson
THE $1 TRILLION MEDTECH QUESTION
At the helm of Johnson & Johnson MedTech, Tim Schmid sits where global portfolio scale, category shifts and investment decisions meet. His perspective matters to the central question of which medical-technology platforms can create the next meaningful wave of growth.
Mike Mahoney
Chairman and Chief Executive Officer
Boston Scientific
THE $1 TRILLION MEDTECH QUESTION
Boston Scientific operates at the point where innovation has to become adoption, scale and durable commercial growth. Mike Mahoney brings the market-leader view on where new device categories can genuinely expand demand rather than simply redistribute share.
Kevin Lobo
Chair and Chief Executive Officer
Stryker
THE $1 TRILLION MEDTECH QUESTION
Stryker has built scale across high-value medical technology through portfolio discipline, innovation and strategic expansion. Kevin Lobo brings the CEO view on where durable MedTech growth is still available — and what separates a genuine growth platform from a crowded category.
Bill Maisel, MD, MPH
Senior Vice President, Regulatory Affairs and Quality Assurance (RAQA)
Intuitive
A GREAT DEVICE ISN'T ENOUGH
The commercial question starts before launch: what evidence, quality discipline and regulatory confidence will a new device need before buyers can trust it? Bill Maisel brings a rare perspective across device regulation and product leadership to where that threshold is moving.
Kelley Moffett
Senior Vice President, Quality, Regulatory and Medical Affairs
Cardinal Health — Global Medical Products and Distribution
THE NEW QUALITY RULEBOOK
Quality systems now sit directly inside supply continuity, market access and commercial credibility. Kelley Moffett brings the manufacturer-and-distribution perspective on what stronger regulatory discipline means when products must move reliably across a complex healthcare supply chain.
Marisa Farabaugh
Senior Vice President and Chief Supply Chain Officer
AdventHealth
WOULD YOUR HOSPITAL ACTUALLY BUY THIS?
The hospital buying decision is where product promise meets system-wide reality. Marisa Farabaugh brings the health-system executive view on the evidence, value, standardization, service and supplier confidence required before a device can move from evaluation into meaningful adoption.
Cairo Wasfy
Vice President, Supply Chain Services and Chief Supply Chain Officer
Orlando Health
WOULD YOUR HOSPITAL ACTUALLY BUY THIS?
A device can be clinically impressive and still fail the hospital buying process. Cairo Wasfy brings the health-system supply-chain view on what turns evaluation into a real purchasing decision: fit, value, standardization, service, resilience and confidence in the supplier behind the product.
Bruce Radcliff
President of Supply Chain Services
Premier
WHO GETS ON THE PURCHASE ORDER?
Medical-device suppliers increasingly face purchasing decisions shaped across sourcing, contracting, analytics and provider priorities. Bruce Radcliff brings the group-purchasing and health-system operating perspective on what suppliers need to do to move from consideration to the purchase order.
Steve Downey
Chief Supply Chain and Patient Support Services Officer
Cleveland Clinic
WHO GETS ON THE PURCHASE ORDER?
For suppliers, winning a major health system is about far more than unit price. Steve Downey brings the integrated provider view on sourcing, contracting, standardization, resilience and patient-support operations — the real filters that determine which products make it onto the purchase order.
Mike Stubee
Vice President, Payor Strategy
Orlando Health
FDA APPROVED. NOW WHO PAYS?
Regulatory clearance does not create a reimbursed market. Mike Stubee brings the provider-payor strategy perspective to the decisions that determine whether a technology can move beyond clinical interest into funded, repeatable adoption.
Emad Rizk, MD
Chief Executive Officer, President and Chairman of the Board
Premier
THE COMMERCIALIZATION GAP
The gap between an approved product and a scaled healthcare business is ultimately an execution problem. Emad Rizk brings the provider-performance perspective on how data, economics, operating discipline and health-system relationships determine whether innovation becomes repeatable adoption.
Lisa Ashby
Chief Executive Officer
Solis Mammography
THE COMMERCIALIZATION GAP
Commercialization succeeds when technology fits the way care is actually delivered and scaled. Lisa Ashby brings the operating perspective of a diagnostics leader building growth around patient access, clinical delivery and a repeatable platform — a useful test of whether innovation can move beyond launch into sustained adoption.
Dr. Taha Kass-Hout
Chief Science & Technology Officer
GE HealthCare
AI HAS ENTERED THE DEVICE
When intelligence becomes part of the product, device strategy changes with it. Taha Kass-Hout brings the enterprise technology view on how AI can be developed, governed and translated into clinical technology that hospitals can actually deploy and trust.
Jim Boyle
Chief Executive Officer
Medline
WHO ACTUALLY GETS YOUR DEVICE INTO THE MARKET?
A strong device still needs commercial reach, logistics and trusted access to healthcare customers. Jim Boyle brings the distribution-scale perspective on what manufacturers need from channel partners — and where direct selling, distribution and strategic relationships create very different paths to market.
Chris Carlson, PhD
Executive Vice President, Research, Corporate Development, Corporate Strategy, and Intuitive Ventures
Intuitive
BUILD IT, BUY IT OR PARTNER?
The next growth platform does not always have to be invented internally. Chris Carlson sits across research, corporate development, strategy and venture investment — exactly where leaders decide whether a capability should be built, acquired, partnered or backed before the market moves.
Tal Wenderow
Founding Managing Partner
Star51 Capital
BUILD IT, BUY IT OR PARTNER?
MedTech capital is increasingly judged by the path from innovation to strategic value, not invention alone. Tal Wenderow brings an operator-investor perspective on which technologies merit backing, what makes a company strategically relevant and when partnership can beat going it alone.
Mark P. Brosius
Chief Manufacturing and Supply Chain Officer
Intuitive
FROM PROTOTYPE TO 100,000 UNITS
A successful prototype proves very little about whether a company can manufacture at scale. Mark Brosius brings the operations view across planning, new-product introduction, manufacturing and logistics — the disciplines that decide whether commercial demand becomes reliable production.
David J. Rosa
Chief Executive Officer and Member of the Board of Directors
Intuitive
IF YOU WERE BUILDING A MEDTECH COMPANY TODAY — WHERE WOULD YOU PLACE THE BET?
The closing question is about where technology, clinical need and scalable business models now intersect. David Rosa brings the perspective of a leader who has worked across engineering, product, commercial strategy and company leadership to judge where the next durable MedTech platforms may emerge.
Conference Agenda
PRODUCT → EVIDENCE → BUYER → PROCUREMENT → REIMBURSEMENT → DISTRIBUTION → PARTNERSHIPS → SCALE
DAY ONE • MAY 11, 2027
FROM PRODUCT TO PURCHASE
9:30 AM
THE $1 TRILLION MEDTECH QUESTION
Where Will the Next Generation of Medical-Device Growth Actually Come From?
10:20 AM
A GREAT DEVICE ISN'T ENOUGH
What Evidence Will Buyers, Regulators and Payors Actually Demand Before They Say Yes?
11:10 AM
EXHIBITION / NETWORKING
11:40 AM
WOULD YOUR HOSPITAL ACTUALLY BUY THIS?
What Makes a Medical Device Move From Evaluation to Purchase?
12:30 PM
LUNCH / EXHIBITION
1:30 PM
WHO GETS ON THE PURCHASE ORDER?
How Medical-Device Procurement Is Changing — and What Suppliers Need to Do About It
2:20 PM
FDA APPROVED. NOW WHO PAYS?
Why Reimbursement Can Decide Whether a Medical Device Ever Reaches Scale
3:10 PM
COFFEE / EXHIBITION
3:40 PM
THE NEW QUALITY RULEBOOK
QMSR Is Here — What Changes When FDA Comes Through the Door?
4:30 PM
THE COMMERCIALIZATION GAP
Why Good Medical Devices Still Fail Between Approval and Adoption
DAY TWO • MAY 12, 2027
FROM MARKET ACCESS TO SCALE
9:30 AM
AI HAS ENTERED THE DEVICE
What Happens When Medical Technology Can Learn, Adapt and Change?
10:20 AM
WHO ACTUALLY GETS YOUR DEVICE INTO THE MARKET?
Direct Sales, Distributors, Strategic Partners — and the Fight for Commercial Reach
11:10 AM
EXHIBITION / NETWORKING
11:40 AM
BUILD IT, BUY IT OR PARTNER?
How MedTech Leaders Decide Where Their Next Growth Platform Comes From
12:30 PM
LUNCH / EXHIBITION
1:30 PM
FROM PROTOTYPE TO 100,000 UNITS
Can You Manufacture the Device You Just Sold?
2:20 PM
THE SUPPLY CHAIN IS NOW A BOARDROOM ISSUE
Can MedTech De-Risk Manufacturing Without Killing Margin?
3:10 PM
COFFEE / EXHIBITION
3:40 PM
THE HOSPITAL WON'T ALWAYS BE THE CUSTOMER
Where Will Medical Devices Be Used — and Bought — Next?
4:30 PM
IF YOU WERE BUILDING A MEDTECH COMPANY TODAY — WHERE WOULD YOU PLACE THE BET?
Conference participation and commercial opportunities
Contact the event team about conference participation, strategic partnerships, sponsorship and appropriate commercial opportunities around the program.
Conference Inquiry